Takahashi Junichiro, Ito Masamichi, Okude Jun, Gohda Toshihiro, Wakamatsu Yutaka, Sasaki Shigeyuki, Yasuda Keishu
Division of Cardiovascular Surgery, Aishin Memorial Hospital, Sapporo, Japan.
Ann Thorac Cardiovasc Surg. 2003 Jun;9(3):192-6.
Antithrombin III (AT III) deficiency is a rare hereditary disease that predisposes to thromboembolic complications. We report a case of AT III deficiency complicated with acute pulmonary thromboembolism, successfully treated with emergency pulmonary thromboembolectomy after insertion of an inferior vena cava filter. AT III activity before treatment was found to be 44% of normal value and remained less than 50% of normal throughout the postoperative course. In his family line, both the patient's aunt and deceased father had a history of pulmonary infarction. AT III activity of the patient's aunt was 47 to 58% of normal value. The patient was discharged on the 15th day after surgery and has been doing well for four years receiving warfarin as anticoagulant therapy. Careful follow-up is essential for early detection of the recurrent pulmonary thromboembolism resulting in pulmonary hypertension and/or right heart failure.
抗凝血酶III(AT III)缺乏症是一种罕见的遗传性疾病,易引发血栓栓塞并发症。我们报告一例AT III缺乏症合并急性肺血栓栓塞症的病例,该患者在植入下腔静脉滤器后成功接受了急诊肺血栓切除术。治疗前AT III活性为正常值的44%,术后整个过程中一直低于正常值的50%。在其家族中,患者的姑姑和已故父亲都有肺梗死病史。患者姑姑的AT III活性为正常值的47%至58%。患者术后第15天出院,接受华法林抗凝治疗四年,情况良好。密切随访对于早期发现复发性肺血栓栓塞导致的肺动脉高压和/或右心衰竭至关重要。